Used in research for the treatment of myelofibrosis, a type of bone marrow disorder. It functions as a JAK2 inhibitor, helping to reduce abnormal signaling in blood cell production. Shows potential in alleviating symptoms such as spleen enlargement and systemic symptoms like fatigue and weight loss. Investigated for its ability to improve quality of life in patients with myeloproliferative diseases. Not approved for commercial use; currently limited to clinical and laboratory research settings.